{"created":"2023-06-20T14:29:14.246210+00:00","id":5268,"links":{},"metadata":{"_buckets":{"deposit":"e6107052-20ce-45af-bf0e-2ea3188e5efc"},"_deposit":{"created_by":14,"id":"5268","owners":[14],"pid":{"revision_id":0,"type":"depid","value":"5268"},"status":"published"},"_oai":{"id":"oai:dmu.repo.nii.ac.jp:00005268","sets":["81:234"]},"author_link":["10171","842","6973","47058"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2022-12-25","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"84","bibliographicPageStart":"75","bibliographicVolumeNumber":"49","bibliographic_titles":[{"bibliographic_title":"Dokkyo Journal of Medical Sciences"}]}]},"item_10001_description_34":{"attribute_name":"要旨","attribute_value_mlt":[{"subitem_description":"　2022年9月現在，COVID-19の小児用mRNAワクチンは約288万回接種され，ワクチンに関連したアナフィラキシーとして報告されたのは9件であった．そのうち，専門家による検討で明らかなアナフィラキシーと判断されたのは2名で，100万接種あたり0.7件の発生率であった．これは既存のワクチンの副反応によるアナフィラキシー発生率と同等と考えられる．ワクチンの副反応はブライトン分類に基づき評価されるが，迷走神経反射を含む予防接種ストレス関連反応等の紛れ込みがみられるため，正確に診断することが必要である．アナフィラキシーが生じた場合は，治療の第一選択であるアドレナリンの筋肉内注射を躊躇せずに行う．\n　mRNAワクチンに含まれるアレルゲンは，ポリエチレングリコール（PEG）である可能性が高いとされる．そのため，これまでにPEGを含む薬剤でアレルギー症状を生じた既往がある者に対するワクチン接種は慎重に判断する必要がある．しかし，接種前にPEGのアレルギー反応を確認する臨床検査は確立していないため，問診によるハイリスク患者の抽出が試みられている．いずれにしても，アナフィラキシーへの対応法を各施設で明文化し，スタッフ間で情報の共有を行うことで，アナフィラキシー発生時，確実に治療を行えるようにしておく必要がある．","subitem_description_type":"Other"}]},"item_10001_description_35":{"attribute_name":"要旨(英)","attribute_value_mlt":[{"subitem_description":"　By September 2022, approximately 2.88 million doses of COVID-19 mRNA vaccine had been administered in Japanese children, and 9 cases of vaccine-related anaphylaxis had been reported. Of these, 2 cases were determined to be definite anaphylaxis by expert review, for an incidence rate of 0.7 cases per million doses. This is equivalent to the incidence of anaphylaxis from adverse reactions to existing vaccines. If anaphylaxis occurs, pediatricians should administer an intramuscular injection of adrenaline, the first choice of treatment for anaphylaxis.\n　The allergen contained in mRNA vaccines is likely to be polyethylene glycol （PEG）. Therefore, we must be cautious in our decision to vaccinate individuals with a history of allergic reactions to PEG-containing agents. However, since no clinical test has been established to confirm allergic reactions to PEG prior to vaccination, efforts are being made to identify high-risk patients by questionnaire. It is necessary for each facility to clearly state how to respond to anaphylaxis and share information among staff so that treatment can be reliably administered in the event of anaphylaxis.","subitem_description_type":"Other"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"獨協医学会"}]},"item_10001_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA00629581","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"03855023","subitem_source_identifier_type":"ISSN"}]},"item_10001_text_24":{"attribute_name":"著者所属","attribute_value_mlt":[{"subitem_text_value":"獨協医科大学医学部 小児科学"},{"subitem_text_value":"獨協医科大学医学部 小児科学"}]},"item_10001_text_25":{"attribute_name":"著者所属(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Department of Pediatrics, Dokkyo Medical University"},{"subitem_text_language":"en","subitem_text_value":"Department of Pediatrics, Dokkyo Medical University"}]},"item_10001_text_33":{"attribute_name":"記事種別","attribute_value_mlt":[{"subitem_text_value":"総説"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"宮本, 学"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"吉原, 重美"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Miyamoto, Manabu","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yoshihara, Shigemi","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2023-01-17"}],"displaytype":"detail","filename":"DJMS-49-2-2.pdf","filesize":[{"value":"862.1 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"DJMS-49-2-宮本-本文","url":"https://dmu.repo.nii.ac.jp/record/5268/files/DJMS-49-2-2.pdf"},"version_id":"eeedd87f-619a-4d13-bb91-88b13b84d22c"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"新型コロナウイルス感染症","subitem_subject_scheme":"Other"},{"subitem_subject":"ワクチン","subitem_subject_scheme":"Other"},{"subitem_subject":"アナフィラキシー","subitem_subject_scheme":"Other"},{"subitem_subject":"予防接種ストレス関連反応","subitem_subject_scheme":"Other"},{"subitem_subject":"ブライトン分類","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"小児における新型コロナウイルスワクチン接種後アナフィラキシーへの対応","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"小児における新型コロナウイルスワクチン接種後アナフィラキシーへの対応"},{"subitem_title":"Management of Anaphylaxis Associated with Vaccination for COVID-19 in Children","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"14","path":["234"],"publish_date":"2023-01-17","publish_status":"0","recid":"5268","relation_version_is_last":true,"title":["小児における新型コロナウイルスワクチン接種後アナフィラキシーへの対応"],"weko_creator_id":"14","weko_shared_id":-1},"updated":"2023-06-20T14:44:20.129406+00:00"}